The PennZone

  • Home
  • Non-profit
  • Books
  • Entertainment
  • Music
  • Marketing
  • Health
  • Legal
  • Artificial Intelligence

Lineus Medical's CEO Vance Clement joins the 2025 Association of Vascular Access Board of Directors
The PennZone/10278784

Trending...
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
Lineus Medical CEO, Vance Clement AVA Logo Lineus Medical
FAYETTEVILLE, Ark. - PennZone -- Vance Clement, CEO of Lineus Medical, has been selected to join the Association of Vascular Access (AVA) Board of Directors as a Director at Large for a two-year term. AVA is an association of healthcare professionals whose mission is to advance the global practice of vascular access, through awareness, advocacy, and education to improve healthcare outcomes. Since 1985, they have worked to improve vascular access care and promote vascular access specialty. During Vance's time on the board, he will highlight the importance of vascular access care, provide support to local vascular access networks (VAN) across the nation, and grow AVA's membership.  When asked about being selected to join the board Vance said, "It is an honor to join the AVA Board of Directors.  I consider AVA to be the preeminent organization for anyone working in the vascular access space.  I look forward to helping AVA grow its membership."

Vance Clement has worked in the medical device industry for over 30 years. He is a frequent speaker at VAN chapter meetings across the country. He has served as the co-founder and CEO of Lineus Medical since 2015 and is passionate about improving IV care and advancing the science around IV care. Under his leadership, Lineus Medical brought the first break away device for medical lines, SafeBreak Vascular, to market.

More on The PennZone
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications.1 When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

1.          Data on File

MKG 0287 Rev 00

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Dave's Auto Services Launches Free Seven-Week Fall Maintenance Series for Boyertown-Area Drivers
  • P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
  • Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
  • From Newcomers to Neighbors: LINC Celebrates the People Who Make the Valley Home
  • Lehigh Valley's Kellyn Featured in National Film Series Exploring the Future of Diabetes Care
  • Top 100 Golf Coach Daniel Guest and Imagen Golf Announce Partnership with Remo Golf at Fairways Golf Club
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Exonerated Movers Launches in Philadelphia on International Wrongful Conviction Day
  • Atlas Advisors President and Founder Mike McGuire Named a 2026 Leader in Business and Finance by LVB
  • Client 1st Financial Founder Michael Fischer Recognized for Building a Relationship-Rooted Career
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 248
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 215
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 170
  • Brévant Guide Launches New National Restaurant Guide Across Canada - 139
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8 - 123
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • SHI Introduces the RP-222B3S, Its Highest-Capacity 4K Pulse Tube Cryocooler
  • Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Mandeville Pests May Pose Serious Health Risks for Your Family

Similar on PennZone

  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us